Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

  • There is currently no data for MXCT

Holding(s) in Company

30 Mar 2016 18:01

RNS Number : 6163T
MaxCyte, Inc.
30 March 2016
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

 

Maxcyte Inc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

 

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

 

An event changing the breakdown of voting rights

Yes

 

Other (please specify):

 

3. Full name of person(s) subject to thenotification obligation:

Legal & General Group Plc (Group)

Legal & General (Unit Trust Managers) Limited (UTM)

Legal & General Investment Management Limited (LGIM)

4. Full name of shareholder(s)  (if different from 3.):

N/A

 

 

5. Date of the transaction and date onwhich the threshold is crossed orreached:

 

29 March 2016

6. Date on which issuer notified:

30 March 2016

7. Threshold(s) that is/are crossed orreached:

 

 

LGIM Above 5 %

UTM Above 5 %

 

 

8. Notified details:

 

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

 

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ord USD 0.01

 Below 5%

LGIM

(As at First notification under DTR Source Book)

 3,500,000

 Below 3%

 3,500,000

-

8.05%

 Below 5%

UTM

(As on First notification under DTR Source Book)

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

Expirationdate

 

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

 

 

Exercise price

 

Expiration date

 

Exercise/Conversion period

 

Number of voting rights instrument refers to

 

 

% of voting rights

 

 

 

Nominal

Delta

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

 3,500,000

LGIM

 

8.05%

 

 3,500,000

UTM

 

8.05%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

Legal & General Group Plc (Direct and Indirect) (Group) ( 3,500,000 - 8.05% = Total Position)

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) ( 3,500,000 - 8.05% = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) ( 3,500,000 - 8.05% = Total Position)

Legal & General (Unit Trust Managers) Limited ( 3,500,000 - 8.05% = UTM)

Legal & General Group Plc (Direct) (L&G)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD)

Legal & General Insurance Holdings Limited (Direct) (LGIH)

Legal & General Assurance (Pensions Management) Limited (PMC)

Legal & General Assurance Society Limited (LGAS & LGPL)

Legal & General Pensions Limited (Direct) (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to holdvoting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of  43,470,461

14. Contact name:

Amy Williams (LGIM)

15. Contact telephone number:

029 2035 4097

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFIDVIIIVIR
Date   Source Headline
26th Jun 20257:00 amRNSCancellation - Maxcyte Inc
25th Jun 20257:00 amRNSLast Day of Dealings on AIM
23rd Jun 20256:00 pmRNSMaxCyte
19th Jun 20257:00 amRNSResult of Annual General Meeting
12th Jun 20257:00 amRNSHolding(s) in Company
11th Jun 20257:00 amRNS-RMaxCyte and Ori Biotech Announce Collaboration
6th Jun 20259:33 amRNSHolding(s) in Company
5th Jun 20252:16 pmRNSHolding(s) in Company
2nd Jun 20255:14 pmRNSTotal Voting Rights
2nd Jun 20254:17 pmRNSHolding(s) in Company
29th May 20257:06 amRNSHolding(s) in Company
23rd May 20254:52 pmRNSHolding(s) in Company
23rd May 20254:26 pmRNSHolding(s) in Company
23rd May 20257:00 amRNSHolding(s) in Company
19th May 20256:05 pmRNSHolding(s) in Company
16th May 20253:12 pmRNSHolding(s) in Company
9th May 20257:00 amRNSFiling of Form 10-Q
8th May 20257:00 amRNSFirst Quarter 2025 Financial Results
2nd May 20254:40 pmRNSTotal Voting Rights
28th Apr 20257:00 amRNSFiling of definitive proxy statement
22nd Apr 20252:43 pmRNSHolding(s) in Company
22nd Apr 20252:37 pmRNSHolding(s) in Company
15th Apr 20255:00 pmRNSHolding(s) in Company
15th Apr 20257:00 amRNSProposed cancellation of trading on AIM
14th Apr 20259:17 amRNSHolding(s) in Company
10th Apr 20257:00 amRNSMaxCyte to Report Q1 2025 Results on May 7, 2025
8th Apr 20253:35 pmRNSHolding(s) in Company
1st Apr 20255:57 pmRNSTotal Voting Rights
26th Mar 202510:14 amRNSCorrection: Vesting of RSUs and PDMR Dealing
26th Mar 20257:00 amRNSVesting of RSUs and PDMR Dealing
25th Mar 202510:30 amRNSHolding(s) in Company
25th Mar 202510:28 amRNSHolding(s) in Company
25th Mar 202510:26 amRNSHolding(s) in Company
25th Mar 202510:22 amRNSHolding(s) in Company
24th Mar 20259:06 amRNSGrant of Options, RSUs and PSUs and PDMR Dealing
19th Mar 20252:07 pmRNSHolding(s) in Company
12th Mar 20257:01 amRNSFiling of Form 10-K for FY ended December 31, 2024
12th Mar 20257:00 amRNSQ4 & FY 2024 Financial Results
4th Mar 20253:38 pmRNSTotal Voting Rights
19th Feb 20253:23 pmRNSHolding(s) in Company
14th Feb 20255:05 pmRNSHolding(s) in Company
13th Feb 20254:12 pmRNSHolding(s) in Company
13th Feb 20252:52 pmRNSHolding(s) in Company
12th Feb 20257:00 amRNSStrategic Platform License with TG Therapeutics
7th Feb 20257:00 amRNSNotice of Results
4th Feb 20257:00 amRNSTotal Voting Rights
31st Jan 20253:18 pmRNSExercise of options and PDMR dealing
30th Jan 20257:00 amRNSMaxCyte® Acquires SeQure Dx
29th Jan 20253:05 pmRNSHolding(s) in Company
22nd Jan 20252:25 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.